Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16437098 | 1.00 | TSHR (0.58) | TSHRNAAASMN1; SMN2NPC1MAPT | |
| SCHEMBL9516494 | 1.00 | TSHR (0.58) | TSHRNAAASMN1; SMN2NPC1MAPT | |
| SCHEMBL1594369 | 1.00 | TSHR (0.58) | TSHRNAAASMN1; SMN2NPC1MAPT | |
| SCHEMBL20120433 | 1.00 | TSHR (0.58) | TSHRNAAASMN1; SMN2NPC1MAPT | |
| SCHEMBL146520 | 0.96 | TSHR (0.64) | TSHRNAAASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL11544338 | 0.93 | TSHR (0.61) | TSHRNAAASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL24773684 | 0.92 | TSHR (0.54) | TSHRNAAASMN1; SMN2NPC1MAPT | |
| SCHEMBL15140027 | 0.89 | TSHR (0.47) | TSHRNAAASMN1; SMN2NPC1MAPT | |
| SCHEMBL15145980 | 0.89 | TSHR (0.47) | TSHRNAAASMN1; SMN2NPC1MAPT | |
| SCHEMBL4608747 | 0.89 | TSHR (0.74) | TSHRNAAASMN1; SMN2TDP1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20230248837-A1 | Technology for Modulating Targeting Chimeras Induced by Cell-Penetrating Peptide and Application Thereof | LIU, MIAO (CN) | 2023-08-10 | — | — | US | disclosed |
| US-10941115-B2 | Kinase inhibitors | OXULAR ACQUISITIONS LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| US-20190330155-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10392346-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-10125100-B2 | Kinase inhibitors | RESPIVERT LIMITED | 2018-11-13 | — | — | US | disclosed |
| US-20180319748-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-11-08 | — | — | US | disclosed |
| US-20180235992-A1 | IMMUNOTHERAPIES FOR MALIGNANT, NEURODEGENERATIVE AND DEMYELINATING DISEASES BY THE USE OF TARGETED NANOCARRIERS | RODOS BIOTARGET GMBH (DE) | 2018-08-23 | — | — | US | disclosed |
| EP-3328367-A1 | IMMUNOTHERAPIES FOR MALIGNANT, NEURODEGENERATIVE AND DEMYELINATING DISEASES BY THE USE OF TARGETED NANOCARRIERS | Rodos BioTarget GmbH (DE) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017017148-A1 | IMMUNOTHERAPIES FOR MALIGNANT, NEURODEGENERATIVE AND DEMYELINATING DISEASES BY THE USE OF TARGETED NANOCARRIERS | RODOS BIOTARGET GMBH (DE) | 2017-02-02 | — | — | WO | disclosed |
| US-20160102059-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| WO-2016051187-A1 | DIARYL UREA DERIVATIVES AS P38 KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2016-04-07 | — | — | WO | disclosed |
| EP-0341409-B1 | Platinum (II) complexes, their preparation and use as antitumour agents | BOEHRINGER MANNHEIM ITALIA (IT) | 1993-12-29 | — | — | EP | disclosed |
| EP-0287042-B1 | 2-SULPHINYL-ACETYL-1,3-THIAZOLIDINES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1992-09-16 | — | — | EP | disclosed |
| EP-0415939-A1 | PLATINUM(II) COMPLEXES, THEIR PREPARATION AND USE AS ANTI-TUMOUR AGENTS | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1991-03-13 | — | — | EP | disclosed |
| EP-0341409-A1 | Platinum (II) complexes, their preparation and use as antitumour agents | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1989-11-15 | — | — | EP | disclosed |
| WO-1989009218-A1 | PLATINUM(II) COMPLEXES, THEIR PREPARATION AND USE AS ANTI-TUMOUR AGENTS | BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1989-10-05 | — | — | WO | disclosed |
| US-4849437-A | 2-sulphinyl-acetyl-1,3-thiazolidines, their preparation and pharmaceutical compositions | BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1989-07-18 | — | — | US | disclosed |
| EP-0287042-A1 | 2-Sulphinyl-acetyl-1,3-thiazolidines, their preparation and pharmaceutical compositions | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1988-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235992-A1 | IMMUNOTHERAPIES FOR MALIGNANT, NEURODEGENERATIVE AND DEMYELINATING DISEASES BY THE USE OF TARGETED NANOCARRIERS | MAG, MSR1, CD47 | TSHR 862/4885NAAA 3546/4885SMN1; SMN2 638/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | TSHR 70/4885NAAA 3147/4885SMN1; SMN2 2865/4885 |
| US-20180319748-A1 | KINASE INHIBITORS | LYN, SYK, BTK | TSHR 2315/4885NAAA 4844/4885SMN1; SMN2 4346/4885 |
| US-10125100-B2 | Kinase inhibitors | SYK, LYN, SRC | TSHR 1681/4885NAAA 4589/4885SMN1; SMN2 3903/4885 |
| US-20190330155-A1 | KINASE INHIBITORS | SYK, LYN, BTK | TSHR 1763/4885NAAA 4349/4885SMN1; SMN2 4531/4885 |
| US-10941115-B2 | Kinase inhibitors | SYK, LYN, BTK | TSHR 1763/4885NAAA 4349/4885SMN1; SMN2 4531/4885 |
| US-20160102059-A1 | KINASE INHIBITORS | SYK, LYN, BTK | TSHR 1571/4885NAAA 4396/4885SMN1; SMN2 4459/4885 |
| US-10392346-B2 | Kinase inhibitors | LYN, SYK, BTK | TSHR 2315/4885NAAA 4844/4885SMN1; SMN2 4346/4885 |
| US-20230248837-A1 | Technology for Modulating Targeting Chimeras Induced by Cell-Penetrating Peptide and Application Thereof | VIP, GHITM, MYCBP | TSHR 1587/4885NAAA 3882/4885SMN1; SMN2 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.